Efficacy of linagliptin on glycemic control in diabetic patients on hemodialysis [Diamond study-1]

Efficacy of linagliptin on glycemic control in diabetic patients on hemodialysis [Diamond study-1] - Efficacy of linagliptin in diabetic patients on hemodialysis [Diamond study-1]

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007635

Enrollment

Registered

2012-04-02

Start date

2012-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic patients on hemodialysis

Interventions

linagliptin voglibose

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diabetic patients on stable regular hemodialysis who have HbA1c (NGSP) >= 4.6% and <= 10.0% (HbA1c (JDS) >= 4.3% and <= 9.6%) or glycated albumin >= 18.0% and <= 30.0%

Exclusion criteria

Exclusion criteria: Patients treated with insulin Patients with severe liver dysfunction (AST >= 100 IU/L or ALT >= 100 IU/L) Patients with malignancy Patients with untreated diabetic retinopathy Patients disqualified by doctor for any reason

Design outcomes

Primary

Measure	Time frame
Change from baseline in HbA1c at week 12	—

Secondary

Measure	Time frame
Change from baseline in glycated albumin at week 12	—

Countries

Japan

Contacts

Public ContactKatsuhito Mori

Osaka City University Graduate School of Medicine 2nd department of internal medicine

ktmori@med.osaka-cu.ac.jp06-6645-3806

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026